Contact Us

Because we operate as a highly specialized, asset-light consultancy, we do not use automated sales sequences. Liz Yasuda, our Principal, personally reviews every inquiry to assess your operating model and current bottlenecks. If your project aligns with our expertise, we will reply within 48 business hours to schedule a 20-minute, confidential Discovery Briefing.

Absolutely. We regularly work with Private Equity firms on M&A due diligence and brand owners protecting proprietary formulations. We understand the highly sensitive nature of FDA compliance liabilities and CMO networks. We are happy to execute a mutual Non-Disclosure Agreement prior to our initial Discovery Briefing.

This depends heavily on our current client roster and the scope of your regulatory needs. For urgent M&A due diligence or critical FDA/regulatory responses, we can often expedite the onboarding process. Please indicate any strict timelines in your project description.

Our focus is on generating systemic, compounding ROI (such as the 40% margin growth highlighted in our case studies). Therefore, we prioritize comprehensive audits, infrastructure builds, and retained advisory roles. However, we do occasionally accept targeted, high-level strategic alignment sessions if a brand is facing an immediate, complex regulatory hurdle.